Navigation Links
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Date:12/8/2009

PITTSBURGH, Dec. 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the generic version of Wyeth's Effexor XR® Capsules, a treatment for major depressive disorder.

Pursuant to the license agreement, Mylan will be granted a non-exclusive license to the relevant patents that would permit Mylan to launch Venlafaxine HCl ER Capsules in the U.S. on or after June 1, 2011, or earlier in limited circumstances. Additional details of the agreement remain confidential.

Venlafaxine HCl ER Capsules had U.S. sales of approximately $2.9 billion for the same strengths for the 12 months ending Sept. 30, according to IMS Health. Currently, Mylan has 129 abbreviated new drug applications (ANDAs) pending U.S. Food and Drug Administration approval representing $85 billion in annual brand sales, according to IMS. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.2 billion in annual brand sales, according to IMS.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
2. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
3. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , Jan. 18, 2017 ... 2022 Summary GlobalData,s new report, "South Korea ... data on the South Korea Insulin Delivery market. The ... (in units) and average prices (USD) within market segments ... Insulin Pump Accessories. The report also provides company ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... "Breast Imaging Technologies Market by Type: Global Opportunity Analysis and ... market size was valued at $2,544 million in 2015 and ... a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. Ionizing ...
(Date:1/18/2017)... Calif. , Jan. 18, 2017  Adaptive Sound Technologies, ... today a new partnership with Hyatt Place Nashville/Downtown to ... providing ASTI LectroFan sleep therapy machines in over two ... of the most important parts of having a great ... general manager of Hyatt Place Nashville/Downtown. "We,re pleased to ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical ... 2017 who are passionate about making a difference in the lives of the ... Tampa, UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni and ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Sam & ... assistance to commercial and residential clients in the California Bay Area, is launching a ... health in the region. , Heart disease is the primary killer of adult men ...
(Date:1/19/2017)... ... ... Tribble Insurance Agency, a family owned and operated firm offering asset protection and ... honor Chad Phillip Dermyer, a local police trooper who was shot and killed serving ... officers were conducting routine stops of suspects when one of them, a violent career ...
(Date:1/19/2017)... ... , ... St. Catherine’s Village announced that a limited number of rooms have ... on the grounds of the St. Catherine’s Village campus in Madison, Mississippi that accommodates ... home in Mississippi for the second year in a row by readers of the ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... taken in the 2017 Spring Create Real Impact contest from Impact Teen Drivers ... 17 at http://www.createrealimpact.com . , Educational grants totaling $15,000 will be ...
Breaking Medicine News(10 mins):